Biogen, a biotechnology company, completed the acquisition of Reata Pharmaceuticals, a biopharmaceutical company, for $7.3bn. “By adding a highly complementary product in an area of significant unmet medical need to our portfolio, we believe the acquisition of Reata aligns with our strategy to serve patients, drive sustainable growth and create significant shareholder value. With the transaction now complete, we look forward to leveraging Biogen’s rare disease expertise and capabilities to work together with our Reata colleagues as one team to bring SKYCLARYS® to patients living with this devastating disease," Christopher A. Viehbacher, Biogen President and CEO.